Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

BioCrine

BioCrine
M&A STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
$3.33M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of pharmaceutical innovations for the treatment of diabetes. The company's goal is to commercialize new concepts of treatment and enable continual delivery of novel drugs both for diabetes itself and for the complications that the disease induces.

Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Parent Company
Primary Office
  • Sveav√§gen 166
  • Box 3073
  • 169 03 Solna
  • Sweden

+46 072-042 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore BioCrine’s full profile, request a free trial.

BioCrine Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 26-Sep-2013 $3.33M Completed Startup
2. Merger/Acquisition 29-Apr-2002 Completed Startup
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

BioCrine Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
HealthCap Venture Capital Minority 000 0000 000000 0

BioCrine Executive Team (3)

Name Title Board
Seat
Contact
Info
Per-Olof Berggren Ph.D Chief Executive Officer & Board Member
Catharina Rahm Chief Financial Officer

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

BioCrine Board Members (5)

Name Representing Role Since Contact
Info
Claes-Henrik Julander Self Board Member 000 0000
Gunnar Olsson Ph.D Self Board Member 000 0000
Kenth Petersson Self Chairman 000 0000
Martin Nicklasson Ph.D Self Board Member 000 0000
Per-Olof Berggren Ph.D BioCrine Chief Executive Officer & Board Member 000 0000